Publications by authors named "Louise H Yu"
Article Synopsis
- Treatment persistence in patients with psoriatic arthritis (PsA) is crucial for achieving effective outcomes, and guselkumab, an interleukin-23 inhibitor, has shown high persistence rates in clinical trials.
- A study analyzed real-world data to compare the treatment persistence between patients using guselkumab and those receiving their first subcutaneous tumor necrosis factor inhibitor (TNFi) from July 2020 to March 2022.
- Results indicated that on-label persistence rates were assessed using statistical models to evaluate the effectiveness of both treatments, highlighting the need for further real-world evidence in comparing these therapies.
Objective: To assess the predictive accuracy of code-based algorithms for identifying invasive ( disease (IED) among inpatient encounters in US hospitals.
Methods: The PINC AI Healthcare Database (10/01/2015-03/31/2020) was used to assess the performance of six published code-based algorithms to identify IED cases among inpatient encounters. Case-confirmed IEDs were identified based on microbiological confirmation of in a normally sterile body site (Group 1) or in urine with signs of sepsis (Group 2).
Introduction: We evaluated the use of rheumatoid arthritis (RA) disease measures in patients with systemic lupus erythematosus (SLE) in a US community-based rheumatology physician network over 5 years.
Methods: This retrospective, observational cohort study (GSK Study 213818) of patients with SLE utilized electronic medical records (01 January 2010-31 December 2019) from the United Rheumatology Normalized Integrated Community Evidence database. The index was the date of first SLE diagnosis recorded in the database; the observation period was 5 years post-index.
Introduction: Therapeutic options for metastatic castration-resistant prostate cancer (mCRPC) patients are continuously advancing. We described mCRPC treatment patterns in the US from 2013 to 2019.
Methods: Patients with a confirmed mCRPC diagnosis and adenocarcinoma histology were included in the US Flatiron Health Electronic Health Record-derived de-identified database.
Introduction: To evaluate the economic burden and treatment patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab, a C5 inhibitor, who were defined as blood transfusion-dependent (TD) versus blood transfusion-free (TF) in the US population.
Methods: Patients aged at least 12 years with at least two claims for eculizumab infusion (first claim was the index date) were identified from the IBM MarketScan Research Databases (April 1, 2014-September 30, 2019). The overall PNH eculizumab user cohort was stratified into the TD cohort (i.